GSK took rights to a cardiovascular siRNA program from China-based SiranBio, targeting ALK7. The agreement covers most global rights but excludes mainland China, Hong Kong, Macau and Taiwan, where ownership remains with SiranBio. SiranBio said it is eligible for more than $1 billion in total payments in addition to royalties, with upfront undisclosed. The deal also references emerging clinical data linking ALK7 knockdown to reductions in visceral fat and potential cardiovascular-risk modulation. For small RNA developers and large pharma BD teams, the key signal is continued appetite for targeted knockdown approaches with differentiated systemic biology—plus a geographic carve-out that reflects how China access is being managed in cross-border licensing.